NASDAQ:PODD - Insulet Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$92.83 -0.32 (-0.34 %)
(As of 05/27/2018 01:28 PM ET)
Previous Close$92.83
Today's Range$92.02 - $93.91
52-Week Range$40.92 - $94.25
Volume251,987 shs
Average Volume451,970 shs
Market Capitalization$5.45 billion
P/E Ratio-201.80
Dividend YieldN/A
Beta1.39

About Insulet (NASDAQ:PODD)

Insulet logoInsulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000

Debt

Debt-to-Equity Ratio3.34
Current Ratio5.48
Quick Ratio5.16

Price-To-Earnings

Trailing P/E Ratio-201.80
Forward P/E Ratio-464.15
P/E GrowthN/A

Sales & Book Value

Annual Sales$463.77 million
Price / Sales11.76
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book32.01

Profitability

EPS (Most Recent Fiscal Year)($0.46)
Net Income$-26,830,000.00
Net Margins-4.82%
Return on Equity-20.02%
Return on Assets-3.60%

Miscellaneous

Employees857
Outstanding Shares58,740,000

Insulet (NASDAQ:PODD) Frequently Asked Questions

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings data on Thursday, May, 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.08. The medical instruments supplier had revenue of $123.60 million for the quarter, compared to analyst estimates of $121.76 million. Insulet had a negative return on equity of 20.02% and a negative net margin of 4.82%. The business's quarterly revenue was up 21.5% compared to the same quarter last year. During the same period last year, the company earned ($0.17) EPS. View Insulet's Earnings History.

When is Insulet's next earnings date?

Insulet is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Insulet.

What price target have analysts set for PODD?

18 brokerages have issued twelve-month price targets for Insulet's shares. Their predictions range from $65.00 to $105.00. On average, they expect Insulet's share price to reach $88.3750 in the next twelve months. View Analyst Ratings for Insulet.

What are Wall Street analysts saying about Insulet stock?

Here are some recent quotes from research analysts about Insulet stock:
  • 1. According to Zacks Investment Research, "INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. " (5/9/2018)
  • 2. Canaccord Genuity analysts commented, "We maintain our BUY rating on PODD following the announcement that the company has secured two new OUS distributor partnerships with Theras Group (Italy) and Nordic Infucare (Nordic countries) effective July 1, 2018. Both distributors will provide sales, marketing, and customer support in their respective regions. We are encouraged to see PODD not only executing on OUS transition milestones but securing experienced medical device distributors in OUS countries. We believe the market exit by JNJ/Animas has created a unique opportunity for pump players – basically everyone ex Medtronic – to step into existing distribution/service networks who were left looking for new products when JNJ announced it was shuttering Animas. Thus, while not underestimating the resources required to build out an OUS commercial organization, the news of these two partnerships leaves us incrementally confident in Insulet’s ability to facilitate a smooth OUS transition." (5/2/2018)

Who are some of Insulet's key competitors?

Who are Insulet's key executives?

Insulet's management team includes the folowing people:
  • Mr. Patrick J. Sullivan, Chairman & CEO (Age 66)
  • Ms. Shacey Petrovic, Pres & COO (Age 44)
  • Mr. Michael L. Levitz, Sr. VP, CFO & Treasurer (Age 44)
  • Mr. Charles Alpuche, Exec. VP & Chief Operations Officer (Age 58)
  • Mr. Bradley A. Thomas, Exec. Officer (Age 60)

Has Insulet been receiving favorable news coverage?

Media stories about PODD stock have trended somewhat positive on Sunday, according to Accern. The research group scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Insulet earned a news sentiment score of 0.19 on Accern's scale. They also gave media coverage about the medical instruments supplier an impact score of 47.06 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Insulet's major shareholders?

Insulet's stock is owned by many different of retail and institutional investors. Top institutional investors include Frontier Capital Management Co. LLC (3.83%), Lord Abbett & CO. LLC (2.06%), Champlain Investment Partners LLC (1.77%), JPMorgan Chase & Co. (1.32%), Northern Trust Corp (1.29%) and OppenheimerFunds Inc. (1.06%). Company insiders that own Insulet stock include Bradley A Thomas, Charles Alpuche, David A Lemoine, James C Mullen, Jessica Hopfield, John A Fallon, Joseph S Zakrzewski, Michael P Spears, Patrick J Sullivan, Regina O Sommer and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

Which institutional investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Loomis Sayles & Co. L P, Point72 Asset Management L.P., Champlain Investment Partners LLC, Segall Bryant & Hamill LLC, A.R.T. Advisors LLC, JPMorgan Chase & Co. and Shaker Investments LLC OH. Company insiders that have sold Insulet company stock in the last year include Bradley A Thomas, Charles Alpuche, David A Lemoine, John A Fallon, Michael P Spears and Shacey Petrovic. View Insider Buying and Selling for Insulet.

Which institutional investors are buying Insulet stock?

PODD stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Rockefeller Capital Management L.P., Wasatch Advisors Inc., Carillon Tower Advisers Inc., OppenheimerFunds Inc., KAMES CAPITAL plc, Victory Capital Management Inc. and Frontier Capital Management Co. LLC. Company insiders that have bought Insulet stock in the last two years include Bradley A Thomas, Charles Alpuche, James C Mullen, Jessica Hopfield, Michael P Spears and Patrick J Sullivan. View Insider Buying and Selling for Insulet.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $92.83.

How big of a company is Insulet?

Insulet has a market capitalization of $5.45 billion and generates $463.77 million in revenue each year. The medical instruments supplier earns $-26,830,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. Insulet employs 857 workers across the globe.

How can I contact Insulet?

Insulet's mailing address is 600 TECHNOLOGY PARK SUITE 200, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]


MarketBeat Community Rating for Insulet (PODD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  455 (Vote Outperform)
Underperform Votes:  389 (Vote Underperform)
Total Votes:  844
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Insulet (NASDAQ:PODD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
18 Wall Street analysts have issued ratings and price targets for Insulet in the last 12 months. Their average twelve-month price target is $88.3750, suggesting that the stock has a possible downside of 4.80%. The high price target for PODD is $105.00 and the low price target for PODD is $65.00. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.782.702.612.67
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $88.3750$76.7778$72.4667$60.5385
Price Target Upside: 4.80% downside13.20% downside4.08% downside14.30% downside

Insulet (NASDAQ:PODD) Consensus Price Target History

Price Target History for Insulet (NASDAQ:PODD)

Insulet (NASDAQ:PODD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$96.00 ➝ $100.00LowView Rating Details
5/4/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$90.00 ➝ $100.00HighView Rating Details
5/4/2018Northland SecuritiesReiterated RatingBuy$100.00LowView Rating Details
5/4/2018OppenheimerSet Price TargetHold$90.00HighView Rating Details
5/3/2018Piper Jaffray CompaniesBoost Price TargetOverweight$88.00 ➝ $90.00HighView Rating Details
4/20/2018Berenberg BankInitiated CoverageBuy$100.00MediumView Rating Details
4/3/2018GuggenheimInitiated CoverageBuy$105.00LowView Rating Details
2/23/2018Jefferies GroupReiterated RatingBuy$90.00LowView Rating Details
2/22/2018CowenReiterated RatingOutperform ➝ Outperform$80.00 ➝ $90.00MediumView Rating Details
2/22/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$76.00 ➝ $87.00HighView Rating Details
2/22/2018StephensReiterated RatingEqual Weight ➝ Equal Weight$60.00 ➝ $81.00HighView Rating Details
2/22/2018BarclaysReiterated RatingOverweight ➝ Overweight$85.00 ➝ $90.00HighView Rating Details
1/8/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$80.00HighView Rating Details
1/8/2018UBSUpgradeMarket Perform ➝ OutperformHighView Rating Details
11/3/2017Robert W. BairdBoost Price TargetOutperform$65.00 ➝ $72.00N/AView Rating Details
10/12/2017Leerink SwannReiterated RatingOutperform$65.00 ➝ $74.00N/AView Rating Details
10/10/2017WedbushReiterated RatingBuy$60.00 ➝ $65.00N/AView Rating Details
7/17/2017BTIG ResearchDowngradeBuy ➝ NeutralMediumView Rating Details
5/25/2017William BlairReiterated RatingOutperform ➝ OutperformLowView Rating Details
5/14/2017B. RileyReiterated RatingNeutral$44.00LowView Rating Details
2/27/2017Feltl & Co.DowngradeBuy ➝ HoldN/AView Rating Details
11/17/2016JPMorgan Chase & Co.Reiterated RatingHold$38.00N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Insulet (NASDAQ:PODD) Earnings History and Estimates Chart

Earnings by Quarter for Insulet (NASDAQ:PODD)

Insulet (NASDAQ:PODD) Earnings Estimates

2018 EPS Consensus Estimate: ($0.26)
2019 EPS Consensus Estimate: $0.32
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185($0.22)($0.04)($0.14)
Q2 20185($0.18)($0.11)($0.13)
Q3 20186($0.10)$0.05$0.02
Q4 20186($0.09)$0.08($0.01)
Q1 20192($0.04)$0.10$0.03
Q2 20192$0.03$0.11$0.07
Q3 20192$0.05$0.19$0.12
Q4 20192$0.10$0.10$0.10

Insulet (NASDAQ PODD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2018        
5/3/2018Q1 2018($0.19)($0.11)$121.76 million$123.60 millionViewN/AView Earnings Details
2/21/2018Q4 2017($0.08)($0.12)$125.16 million$130.50 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.10)($0.04)$114.02 million$121.80 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.13)($0.13)$106.23 million$110.00 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.16)($0.17)$97.73 million$101.70 millionViewListenView Earnings Details
2/27/2017Q416($0.05)($0.16)$100.61 million$103.58 millionViewListenView Earnings Details
11/3/2016Q316($0.09)($0.05)$89.75 million$94.90 millionViewN/AView Earnings Details
8/3/2016Q216($0.17)($0.08)$81.10 million$87.30 millionViewN/AView Earnings Details
4/28/2016Q116($0.19)($0.19)$79.06 million$81.21 millionViewListenView Earnings Details
2/25/2016Q415($0.26)($0.48)$91.89 million$100.10 millionViewListenView Earnings Details
11/5/2015Q315($0.26)($0.33)$83.56 million$87.30 millionViewListenView Earnings Details
8/12/2015Q215($0.13)($0.27)$70.32 million$75.60 millionViewListenView Earnings Details
4/30/2015Q115($0.10)($0.21)$68.20 million$61.20 millionViewN/AView Earnings Details
2/26/2015Q414($0.04)($0.10)$73.52 million$72.60 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.06)$72.94 million$72.00 millionViewN/AView Earnings Details
5/7/2014Q114($0.06)($0.11)$68.47 million$69.20 millionViewN/AView Earnings Details
2/27/2014Q413($0.09)($0.04)$67.94 million$68.53 millionViewN/AView Earnings Details
11/7/2013Q313($0.16)($0.39)$62.01 million$61.10 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.19)($0.20)$60.47 million$60.09 millionViewN/AView Earnings Details
5/6/2013Q1 2013($0.21)($0.20)$57.26 million$57.40 millionViewN/AView Earnings Details
2/27/2013Q4 2012($0.21)($0.21)$59.12 million$57.80 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.26)$54.93 million$54.80 millionViewN/AView Earnings Details
8/8/2012($0.25)($0.30)ViewN/AView Earnings Details
5/9/2012($0.28)($0.31)ViewN/AView Earnings Details
2/9/2012($0.26)($0.30)ViewN/AView Earnings Details
11/3/2011($0.25)($0.29)ViewN/AView Earnings Details
8/2/2011($0.21)($0.42)ViewN/AView Earnings Details
5/9/2011($0.22)($0.22)ViewN/AView Earnings Details
2/15/2011($0.26)($0.50)ViewN/AView Earnings Details
11/9/2010Q3 2010($0.30)($0.30)ViewN/AView Earnings Details
7/29/2010Q2 2010($0.35)($0.36)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.38)($0.37)ViewN/AView Earnings Details
2/9/2010Q4 2009($0.50)($0.43)ViewN/AView Earnings Details
10/26/2009Q3 2009($0.70)($0.88)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.67)($0.73)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.65)($0.71)ViewN/AView Earnings Details
3/5/2009Q4 2008($0.63)($0.72)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.74)($0.75)ViewN/AView Earnings Details
8/12/2008Q2 2008($0.71)($0.87)ViewN/AView Earnings Details
5/13/2008Q1 2008($0.52)($0.73)ViewN/AView Earnings Details
3/17/2008Q4 2007($0.50)($0.59)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Insulet (NASDAQ:PODD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insulet (NASDAQ PODD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.60%
Insider Trading History for Insulet (NASDAQ:PODD)
Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Insulet (NASDAQ PODD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2018Michael P. SpearsSVPSell7,774$87.77$682,323.98View SEC Filing  
5/15/2018Michael P. SpearsSVPSell8,114$86.64$702,996.96View SEC Filing  
5/1/2018David A. LemoineDirectorSell1,084$84.93$92,064.12View SEC Filing  
3/16/2018Bradley A. ThomasEVPSell3,500$85.00$297,500.00View SEC Filing  
3/15/2018Charles AlpucheCOOSell7,090$84.65$600,168.50View SEC Filing  
3/14/2018Bradley A. ThomasEVPSell7,250$83.81$607,622.50View SEC Filing  
3/14/2018John A. FallonDirectorSell9,000$84.10$756,900.00View SEC Filing  
3/6/2018David A. LemoineDirectorSell641$76.81$49,235.21View SEC Filing  
3/6/2018Shacey PetrovicCOOSell1,319$76.81$101,312.39View SEC Filing  
11/13/2017James C. MullenDirectorBuy2,500$67.45$168,625.00View SEC Filing  
9/6/2017Charles AlpucheEVPBuy2,500$58.08$145,200.00View SEC Filing  
5/16/2017Michael P. SpearsSVPBuy2,500$40.59$101,475.00View SEC Filing  
5/11/2017Bradley A. ThomasEVPBuy3,000$38.69$116,070.00View SEC Filing  
5/11/2017Jessica HopfieldDirectorBuy2,580$38.68$99,794.40View SEC Filing  
5/1/2017David A. LemoineDirectorSell1,524$43.40$66,141.60View SEC Filing  
3/13/2017Regina O. SommerDirectorSell40,000$45.00$1,800,000.00View SEC Filing  
3/6/2017David A. LemoineDirectorSell1,282$45.15$57,882.30View SEC Filing  
3/2/2017Joseph S. ZakrzewskiDirectorSell40,000$46.86$1,874,400.00View SEC Filing  
12/9/2016Charles AlpucheSVPBuy6,600$37.70$248,820.00View SEC Filing  
12/2/2016Patrick J. SullivanCEOBuy40,000$33.89$1,355,600.00View SEC Filing  
12/1/2016Bradley A. ThomasEVPBuy3,100$32.45$100,595.00View SEC Filing  
5/25/2016Regina O SommerDirectorSell8,019$30.42$243,937.9820,330View SEC Filing  
5/18/2016Patrick J SullivanCEOBuy45,000$27.00$1,215,000.00202,795View SEC Filing  
5/13/2016Bradley A ThomasEVPBuy2,975$26.63$79,224.2551,315View SEC Filing  
5/5/2016Bradley A ThomasEVPBuy1,656$30.13$49,895.2848,340View SEC Filing  
3/10/2016Daniel J LevangieInsiderSell12,299$30.89$379,916.1125,358View SEC Filing  
3/7/2016Daniel J LevangieInsiderSell7,663$31.15$238,702.459,813View SEC Filing  
3/2/2016Jessica HopfieldDirectorBuy3,230$30.91$99,839.308,838View SEC Filing  
6/5/2015Patrick J SullivanCEOBuy10,000$29.39$293,900.00View SEC Filing  
5/28/2015Patrick J SullivanCEOBuy20,000$27.91$558,200.00View SEC Filing  
5/15/2015Timothy J ScannellDirectorBuy3,500$27.05$94,675.00View SEC Filing  
5/5/2015Bradley A ThomasEVPBuy1,000$27.26$27,260.00View SEC Filing  
5/5/2015Patrick RyanCOOBuy3,669$26.99$99,026.31View SEC Filing  
4/2/2015R Anthony DiehlGeneral CounselSell3,372$30.96$104,397.12View SEC Filing  
3/9/2015Patrick J SullivanCEOBuy10,000$31.93$319,300.00View SEC Filing  
3/2/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  
2/12/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  
1/2/2015Charles T LiamosDirectorSell4,000$46.08$184,320.00View SEC Filing  
11/3/2014Charles T LiamosDirectorSell4,000$42.95$171,800.00View SEC Filing  
10/1/2014Charles T LiamosDirectorSell4,000$36.58$146,320.00View SEC Filing  
10/1/2014R Anthony DiehlGeneral CounselSell1,250$36.59$45,737.50View SEC Filing  
9/10/2014Charles T LiamosDirectorSell4,000$35.17$140,680.00View SEC Filing  
9/2/2014Duane DesistoCEOSell20,000$36.30$726,000.00View SEC Filing  
8/1/2014Duane DesistoCEOSell20,000$34.23$684,600.00View SEC Filing  
7/1/2014Duane DesistoCEOSell20,000$40.52$810,400.00View SEC Filing  
7/1/2014R Anthony DiehlGeneral CounselSell1,250$39.65$49,562.50View SEC Filing  
6/11/2014R Anthony DiehlGeneral CounselSell17,871$37.09$662,835.39View SEC Filing  
6/9/2014Peter DevlinInsiderSell12,314$37.10$456,849.40View SEC Filing  
4/8/2014Peter DevlinInsiderSell30,000$41.25$1,237,500.0079,668View SEC Filing  
4/3/2014R Anthony DiehlGeneral CounselSell4,617$48.67$224,709.3953,246View SEC Filing  
3/6/2014R Anthony DiehlGeneral CounselSell12,458$49.28$613,930.2458,246View SEC Filing  
3/6/2014Tracey Haas WielinskiVPSell8,275$49.21$407,212.7524,000View SEC Filing  
2/3/2014Charles LiamosDirectorSell11,037$42.93$473,818.4177,316View SEC Filing  
2/3/2014Duane DesistoCEOSell20,000$42.95$859,000.00184,293View SEC Filing  
2/3/2014Peter DevlinInsiderSell30,000$42.82$1,284,600.0063,081View SEC Filing  
1/3/2014Charles LiamosCOOSell86,000$36.02$3,097,720.0077,316View SEC Filing  
1/2/2014Duane DesistoCEOSell20,000$36.07$721,400.00184,293View SEC Filing  
12/3/2013Charles LiamosCOOSell63,808$36.26$2,313,678.08118,194View SEC Filing  
11/18/2013Charles LiamosCOOSell80,000$35.60$2,848,000.00118,194View SEC Filing  
9/3/2013Duane DesistoCEOSell20,000$33.38$667,600.00182,433View SEC Filing  
8/29/2013Sally CrawfordDirectorSell9,000$33.42$300,780.007,000View SEC Filing  
8/15/2013Regina SommerDirectorSell5,000$33.32$166,600.0016,500View SEC Filing  
8/1/2013Duane DesistoCEOSell20,000$31.85$637,000.00View SEC Filing  
7/1/2013Duane DesistoCEOSell20,000$31.51$630,200.00View SEC Filing  
7/1/2013Peter DevlinInsiderSell30,000$31.48$944,400.00View SEC Filing  
6/14/2013Sally CrawfordDirectorSell31,000$30.47$944,570.00View SEC Filing  
6/10/2013R Anthony DiehlGeneral CounselSell38,455$30.50$1,172,877.50View SEC Filing  
6/3/2013Duane DesistoCEOSell20,000$29.76$595,200.00View SEC Filing  
12/3/2012Brian K RobertsCFOSell10,000$21.92$219,200.00View SEC Filing  
11/1/2012Brian K RobertsCFOSell10,000$21.49$214,900.00View SEC Filing  
9/4/2012Brian K RobertsCFOSell10,000$20.78$207,800.00View SEC Filing  
9/4/2012Duane DesistoCEOSell20,000$20.97$419,400.00View SEC Filing  
9/4/2012Ruthann DepietroVPSell1,000$20.90$20,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Insulet (NASDAQ PODD) News Headlines

Source:
DateHeadline
Insulet Co. (PODD) Expected to Announce Quarterly Sales of $132.89 MillionInsulet Co. (PODD) Expected to Announce Quarterly Sales of $132.89 Million
www.americanbankingnews.com - May 27 at 3:06 AM
Five Top MedTech Stocks in DiabetesFive Top MedTech Stocks in Diabetes
finance.yahoo.com - May 25 at 4:59 PM
 Brokerages Expect Insulet Co. (PODD) Will Post Earnings of -$0.13 Per Share Brokerages Expect Insulet Co. (PODD) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - May 25 at 11:19 AM
Insulet Co. (PODD) Given Consensus Rating of "Buy" by BrokeragesInsulet Co. (PODD) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 24 at 9:42 PM
Canaccord Genuity Raises Insulet (PODD) Price Target to $100.00Canaccord Genuity Raises Insulet (PODD) Price Target to $100.00
www.americanbankingnews.com - May 23 at 11:55 AM
Reviewing Insulet (PODD) and Its RivalsReviewing Insulet (PODD) and Its Rivals
www.americanbankingnews.com - May 23 at 5:35 AM
Insider Selling: Insulet Co. (PODD) SVP Sells 7,774 Shares of StockInsider Selling: Insulet Co. (PODD) SVP Sells 7,774 Shares of Stock
www.americanbankingnews.com - May 22 at 7:28 PM
Global Artificial Pancreas Device Systems Market Growth Opportunities: Medtronic, Insulet CorporationGlobal Artificial Pancreas Device Systems Market Growth Opportunities: Medtronic, Insulet Corporation
www.marketwatch.com - May 22 at 8:57 AM
Insulet (PODD) & The Competition Critical ReviewInsulet (PODD) & The Competition Critical Review
www.americanbankingnews.com - May 17 at 11:14 PM
Insulet (PODD) versus Its Peers Head to Head ComparisonInsulet (PODD) versus Its Peers Head to Head Comparison
www.americanbankingnews.com - May 17 at 5:10 PM
Insider Selling: Insulet Co. (PODD) SVP Sells 8,114 Shares of StockInsider Selling: Insulet Co. (PODD) SVP Sells 8,114 Shares of Stock
www.americanbankingnews.com - May 16 at 7:32 PM
Head-To-Head Review: Insulet (PODD) and Its CompetitorsHead-To-Head Review: Insulet (PODD) and Its Competitors
www.americanbankingnews.com - May 15 at 5:19 AM
Insulet Co. (PODD) Forecasted to Post Q2 2018 Earnings of ($0.14) Per ShareInsulet Co. (PODD) Forecasted to Post Q2 2018 Earnings of ($0.14) Per Share
www.americanbankingnews.com - May 11 at 8:35 AM
Comparing Insulet (PODD) and The CompetitionComparing Insulet (PODD) and The Competition
www.americanbankingnews.com - May 11 at 5:24 AM
Endologix (ELGX) vs. Insulet (PODD) Head-To-Head ComparisonEndologix (ELGX) vs. Insulet (PODD) Head-To-Head Comparison
www.americanbankingnews.com - May 10 at 5:14 AM
Insulet Co. (PODD) Expected to Announce Quarterly Sales of $132.79 MillionInsulet Co. (PODD) Expected to Announce Quarterly Sales of $132.79 Million
www.americanbankingnews.com - May 10 at 4:50 AM
Insulet (PODD) Downgraded to "Hold" at Zacks Investment ResearchInsulet (PODD) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 9 at 3:12 PM
Commit To Purchase Insulet Corp At $65, Earn 5.6% Annualized Using OptionsCommit To Purchase Insulet Corp At $65, Earn 5.6% Annualized Using Options
www.nasdaq.com - May 8 at 4:48 PM
Insulet (PODD) Lifted to "Buy" at Zacks Investment ResearchInsulet (PODD) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 8 at 3:33 PM
 Analysts Anticipate Insulet Co. (PODD) Will Announce Earnings of -$0.16 Per Share Analysts Anticipate Insulet Co. (PODD) Will Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - May 8 at 5:18 AM
FY2019 EPS Estimates for Insulet Co. Increased by Piper Jaffray (PODD)FY2019 EPS Estimates for Insulet Co. Increased by Piper Jaffray (PODD)
www.americanbankingnews.com - May 7 at 5:01 AM
Q2 2019 Earnings Forecast for Insulet Co. (PODD) Issued By William BlairQ2 2019 Earnings Forecast for Insulet Co. (PODD) Issued By William Blair
www.americanbankingnews.com - May 7 at 4:38 AM
Insulet Co. (PODD) Forecasted to Post Q1 2019 Earnings of $0.10 Per ShareInsulet Co. (PODD) Forecasted to Post Q1 2019 Earnings of $0.10 Per Share
www.americanbankingnews.com - May 7 at 4:26 AM
Insulet Co. Forecasted to Earn Q4 2018 Earnings of $0.01 Per Share (PODD)Insulet Co. Forecasted to Earn Q4 2018 Earnings of $0.01 Per Share (PODD)
www.americanbankingnews.com - May 7 at 4:18 AM
Insulet (PODD) Stock Rating Reaffirmed by Northland SecuritiesInsulet (PODD) Stock Rating Reaffirmed by Northland Securities
www.americanbankingnews.com - May 5 at 12:55 AM
Insulet (PODD) PT Set at $90.00 by OppenheimerInsulet (PODD) PT Set at $90.00 by Oppenheimer
www.americanbankingnews.com - May 4 at 10:31 PM
Insulet (PODD) Announces Quarterly  Earnings Results, Beats Estimates By $0.08 EPSInsulet (PODD) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS
www.americanbankingnews.com - May 4 at 5:58 PM
Insulet Delivers 21% Revenue Growth and Achieves Operating Profitability BreakevenInsulet Delivers 21% Revenue Growth and Achieves Operating Profitability Breakeven
finance.yahoo.com - May 4 at 4:44 PM
Insulet (PODD) Price Target Increased to $100.00 by Analysts at BMO Capital MarketsInsulet (PODD) Price Target Increased to $100.00 by Analysts at BMO Capital Markets
www.americanbankingnews.com - May 4 at 3:51 PM
Insulet (PODD) Tops Q1 EPS by 8cInsulet (PODD) Tops Q1 EPS by 8c
www.streetinsider.com - May 4 at 9:01 AM
Insulet (PODD) Q1 2018 Results - Earnings Call TranscriptInsulet (PODD) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 9:01 AM
Edited Transcript of PODD earnings conference call or presentation 3-May-18 8:30pm GMTEdited Transcript of PODD earnings conference call or presentation 3-May-18 8:30pm GMT
finance.yahoo.com - May 4 at 9:01 AM
Critical Comparison: Insulet (PODD) & Its CompetitorsCritical Comparison: Insulet (PODD) & Its Competitors
www.americanbankingnews.com - May 4 at 1:20 AM
Insulet (PODD) Price Target Raised to $90.00 at Piper JaffrayInsulet (PODD) Price Target Raised to $90.00 at Piper Jaffray
www.americanbankingnews.com - May 3 at 10:04 PM
Insulet beats by $0.08, beats on revenueInsulet beats by $0.08, beats on revenue
seekingalpha.com - May 3 at 4:43 PM
Insulet Reports First Quarter 2018 Revenue of $123.6 Million, Up 21% Year-Over-Year, and Gross Margin of 61.4%, Up 300 Basis Points, Exceeding ExpectationsInsulet Reports First Quarter 2018 Revenue of $123.6 Million, Up 21% Year-Over-Year, and Gross Margin of 61.4%, Up 300 Basis Points, Exceeding Expectations
finance.yahoo.com - May 3 at 4:43 PM
Insulet: 1Q Earnings SnapshotInsulet: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 4:43 PM
Insulet (PODD) Rating Increased to Strong-Buy at ValuEngineInsulet (PODD) Rating Increased to Strong-Buy at ValuEngine
www.americanbankingnews.com - May 2 at 10:54 PM
Insider Selling: Insulet Co. (PODD) Director Sells 1,084 Shares of StockInsider Selling: Insulet Co. (PODD) Director Sells 1,084 Shares of Stock
www.americanbankingnews.com - May 2 at 7:58 PM
Insulet (PODD) Earns "Buy" Rating from Canaccord GenuityInsulet (PODD) Earns "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - May 2 at 1:04 PM
BRIEF-Insulet Establishes Two Significant Commercial Partnerships To Support Its European ExpansionBRIEF-Insulet Establishes Two Significant Commercial Partnerships To Support Its European Expansion
www.reuters.com - May 2 at 9:03 AM
Insulet Establishes Two Significant Commercial Partnerships to Support its European ExpansionInsulet Establishes Two Significant Commercial Partnerships to Support its European Expansion
finance.yahoo.com - May 1 at 4:40 PM
Analyzing Insulet (PODD) and Its CompetitorsAnalyzing Insulet (PODD) and Its Competitors
www.americanbankingnews.com - April 30 at 5:21 AM
Insulet Co. (PODD) Receives Average Rating of "Buy" from BrokeragesInsulet Co. (PODD) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 29 at 9:30 PM
Insulet (PODD) Rating Lowered to Strong Sell at Zacks Investment ResearchInsulet (PODD) Rating Lowered to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - April 26 at 7:48 AM
Insulet (PODD) Scheduled to Post Earnings on ThursdayInsulet (PODD) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - April 26 at 1:56 AM
Global Insulin delivery system Market Competitive landscape: Insulet Corporation, Animas CorporationGlobal Insulin delivery system Market Competitive landscape: Insulet Corporation, Animas Corporation
www.marketwatch.com - April 24 at 9:03 AM
 Brokerages Anticipate Insulet Co. (PODD) Will Announce Quarterly Sales of $121.60 Million Brokerages Anticipate Insulet Co. (PODD) Will Announce Quarterly Sales of $121.60 Million
www.americanbankingnews.com - April 23 at 5:32 AM
Zacks: Analysts Expect Insulet Co. (PODD) Will Announce Earnings of -$0.19 Per ShareZacks: Analysts Expect Insulet Co. (PODD) Will Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 21 at 1:20 AM
Insulet (PODD) Earns Buy Rating from Analysts at Berenberg BankInsulet (PODD) Earns Buy Rating from Analysts at Berenberg Bank
www.americanbankingnews.com - April 20 at 9:22 AM

SEC Filings

Insulet (NASDAQ:PODD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Insulet (NASDAQ:PODD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Insulet (NASDAQ PODD) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.